Novartis AG ADR (NVS)vsRecursion Pharmaceuticals Inc (RXRX)
NVS
Novartis AG ADR
$160.50
-0.19%
HEALTHCARE · Cap: $302.86B
RXRX
Recursion Pharmaceuticals Inc
$2.91
-8.79%
HEALTHCARE · Cap: $2.37B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 83972% more annual revenue ($57.36B vs $68.23M). NVS leads profitability with a 17.5% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 48/100 (D+).
NVS
Hold48
out of 100
Grade: D+
RXRX
Hold35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-67.6%
Fair Value
$95.76
Current Price
$160.50
$64.74 premium
Intrinsic value data unavailable for RXRX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 34.0%
Every $100 of equity generates 27 in profit
Generating 4.8B in free cash flow
Revenue surging 258.5% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Trading at 8.1x book value
4.7% revenue growth
Grey zone — moderate risk
0.0% earnings growth
0.0% margin — thin
ROE of -54.6% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Operating Margin, Return on Equity. Profitability is solid with margins at 17.5% and operating margin at 34.0%.
Bull Case : RXRX
The strongest argument for RXRX centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 258.5% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Bear Case : RXRX
The primary concerns for RXRX are EPS Growth, Profit Margin, Return on Equity.
Key Dynamics to Monitor
NVS profiles as a value stock while RXRX is a hypergrowth play — different risk/reward profiles.
RXRX carries more volatility with a beta of 1.15 — expect wider price swings.
RXRX is growing revenue faster at 258.5% — sustainability is the question.
NVS generates stronger free cash flow (4.8B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (48/100 vs 35/100), backed by strong 17.5% margins. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Recursion Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that decodes biology by integrating technological innovations in biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company is headquartered in Salt Lake City, Utah.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?